BioAge Labs, Inc. (BIOA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, BioAge Labs reported revenue of $9.0M. Net income was -$80.6M (a -896.1% net margin), or -$2.24 per diluted share. Operating margin was -1031.5%. Operating activities generated -$81.6M of cash, leaving -$82.3M of free cash flow. At fiscal year end, BioAge Labs held $294.9M in total assets against $22.8M in total liabilities, including $188.9M of cash and equivalents.
Open the full interactive BioAge Labs financials → Quarterly statements, key ratios, valuation history and price charts.
BioAge Labs Key Stats
| Share Price | $5.57 |
|---|---|
| Market Cap | $249.8M |
| 52-Week Range | $5.11 – $25.10 |
| Shares Outstanding | 44.8 million (basic, 2026 Q2) |
BioAge Labs Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $9.0M |
| Operating Income | -$78.2M | -$92.8M |
| Pre-Tax Income | -$71.1M | -$80.6M |
| Income Tax | $0 | $0 |
| Net Income | -$71.1M | -$80.6M |
| Diluted EPS | -$6.63 | -$2.24 |
BioAge Labs Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.1M | $3.1M | $2.8M | $2.5M |
| Net Income | -$20.2M | -$25.9M | -$22.3M | -$26.1M |
| Diluted EPS | -$0.56 | -$0.72 | -$0.52 | -$0.58 |
BioAge Labs Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $354.3M | $188.9M |
| Current Assets | $357.1M | $286.8M |
| Total Assets | $358.2M | $294.9M |
| Current Liabilities | $27.8M | $20.1M |
| Total Long-Term Debt | $8.5M | $2.6M |
| Total Liabilities | $35.1M | $22.8M |
| Shareholders' Equity | $323.1M | $272.1M |
BioAge Labs Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$51.5M | -$81.6M |
| Cash From Investing | -$366,000 | -$95.2M |
| Cash From Financing | $381.2M | $11.5M |
| Free Cash Flow | -$51.9M | -$82.3M |
Figures from BioAge Labs' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BioAge Labs financials page for every line item.
BioAge Labs Company Profile
| Ticker | BIOA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Emeryville, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001709941 |
Frequently Asked Questions
What was BioAge Labs' revenue in fiscal 2025?
BioAge Labs (BIOA) reported revenue of $9.0M for fiscal 2025.
What was BioAge Labs' net income in fiscal 2025?
BioAge Labs reported net income of -$80.6M for fiscal 2025.
What was BioAge Labs' earnings per share (EPS) in fiscal 2025?
BioAge Labs' diluted EPS was -$2.24 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did BioAge Labs generate in fiscal 2025?
BioAge Labs generated -$82.3M of free cash flow in fiscal 2025.
What was BioAge Labs' revenue last quarter?
In its most recent reported quarter (2026 Q2), BioAge Labs reported revenue of $2.5M.
How much debt does BioAge Labs have?
BioAge Labs reported $2.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of BioAge Labs are outstanding?
BioAge Labs reported a weighted average of 44.8 million basic shares outstanding in 2026 Q2.
What is BioAge Labs' market cap?
Based on its latest closing price, BioAge Labs (BIOA) has a market capitalization of about $249.8M.
When does BioAge Labs' fiscal year end?
BioAge Labs' fiscal year end, as registered with the SEC, is December 31.
Where is BioAge Labs headquartered?
BioAge Labs lists its business address in Emeryville, California in its SEC filings.